Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00348140




Registration number
NCT00348140
Ethics application status
Date submitted
30/06/2006
Date registered
4/07/2006
Date last updated
5/09/2017

Titles & IDs
Public title
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Scientific title
A 54 Week, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Acetylcholinesterase Inhibitors on Cognition and Overall Clinical Response in APOE4-stratified Subjects With Mild to Moderate Alzheimer's Disease
Secondary ID [1] 0 0
AVA102670
Universal Trial Number (UTN)
Trial acronym
REFLECT-3
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alzheimer's Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Rosiglitazone Extended Release 2mg
Treatment: Drugs - Rosiglitazone Extended Release 8mg
Other interventions - Placebo

Experimental: Arm 1 - Rosiglitazone Extended Release 2mg OD

Experimental: Arm 2 - Rosiglitazone Extended Release 8mg OD

Placebo comparator: Arm 3 - Placebo


Treatment: Drugs: Rosiglitazone Extended Release 2mg
Rosiglitazone Extended Release 2mg OD

Treatment: Drugs: Rosiglitazone Extended Release 8mg
Rosiglitazone Extended Release 8mg OD

Other interventions: Placebo
Placebo
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48, as a Function of APOE e4 Status in APOE4 Negatives Cohort
Timepoint [1] 0 0
Baseline (Week 0) and Week 48
Primary outcome [2] 0 0
Change From Baseline in ADAS-Cog Total Score at Week 48, as a Function of APOE e4 Status in All Except E4/E4s Cohort
Timepoint [2] 0 0
Baseline (Week 0) and Week 48
Primary outcome [3] 0 0
Change From Baseline in ADAS-Cog Total Score at Week 48, as a Function of APOE e4 Status in Full Population Cohort
Timepoint [3] 0 0
Baseline (Week 0) and Week 48
Primary outcome [4] 0 0
Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score at Week 48, as a Function of APOE e4 Status in APOE4 Negatives Cohort
Timepoint [4] 0 0
Baseline (Week 0) and Week 48
Primary outcome [5] 0 0
Change From Baseline in CDR-SB Score at Week 48, as a Function of APOE e4 Status in All Except E4/E4s Cohort
Timepoint [5] 0 0
Baseline (Week 0) and Week 48
Primary outcome [6] 0 0
Change From Baseline in CDR-SB Score at Week 48, as a Function of APOE e4 Status in Full Population Cohort
Timepoint [6] 0 0
Baseline (Week 0) and Week 48
Secondary outcome [1] 0 0
Change From Baseline in ADAS-Cog Total Score at Weeks 8, 16, 24 and 36
Timepoint [1] 0 0
Baseline (Week 0) and Week 8, 16, 24, 36
Secondary outcome [2] 0 0
Change From Baseline in CDR-SB Score at Weeks 12, 24 and 36
Timepoint [2] 0 0
Baseline (Week 0) and Week 12, 24, 36
Secondary outcome [3] 0 0
Change From Screening in Mini Mental State Examination (MMSE) Total Score
Timepoint [3] 0 0
Screening (Week -4) and Week 48
Secondary outcome [4] 0 0
Change From Baseline in Disability Assessment for Dementia (DAD) Total Score
Timepoint [4] 0 0
Baseline (Week 0) and Week 8, 16, 24, 48
Secondary outcome [5] 0 0
Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score
Timepoint [5] 0 0
Baseline (Week 0) and Week 8, 16, 24, 48
Secondary outcome [6] 0 0
Change From Baseline in Domains of the Resource Utilization in Dementia Scale (RUD)- Q1 and Q2 Caregiver Hours
Timepoint [6] 0 0
Baseline (Week 0) and Week 12, 24, 36, 48
Secondary outcome [7] 0 0
Change From Baseline in European Quality of Life -5 Dimensions (EQ-5D) Scale Total Score- Thermometer Score
Timepoint [7] 0 0
Baseline (Week 0) and Week 12, 36, 48
Secondary outcome [8] 0 0
Change From Baseline in EQ-5D Scale Total Score- Utility Score
Timepoint [8] 0 0
Baseline (Week 0) and Week 12, 36, 48
Secondary outcome [9] 0 0
Change From Baseline in Alzheimer's Carer's Quality of Life Instrument (ACQLI) Score
Timepoint [9] 0 0
Baseline (Week 0) and Week 12, 36, 48
Secondary outcome [10] 0 0
Change in ADAS-Cog Total Score for Observed Cases at Week 54 Compared to Week 48
Timepoint [10] 0 0
Week 48 and Week 54
Secondary outcome [11] 0 0
Change in CDR-SB Total Score for Observed Cases at Week 54 Compared to Week 48
Timepoint [11] 0 0
Week 48 and Week 54
Secondary outcome [12] 0 0
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 48
Timepoint [12] 0 0
Baseline (Week 0) and Week 48
Secondary outcome [13] 0 0
Number of Participants With On-treatment Adverse Events (AEs), Serious Adverse Events (SAEs) and Severity of AEs
Timepoint [13] 0 0
Upto Week 48
Secondary outcome [14] 0 0
Number of Participants With Change From Baseline in Vital Signs of Clinical Concern at Any Time on Treatment- Weight
Timepoint [14] 0 0
Upto Week 54
Secondary outcome [15] 0 0
Number of Participants With Change From Baseline in Vital Signs of Clinical Concern at Any Time on Treatment- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Timepoint [15] 0 0
Upto Week 54
Secondary outcome [16] 0 0
Number of Participants With Change From Baseline in Vital Signs of Clinical Concern at Any Time on Treatment- Heart Rate (HR)
Timepoint [16] 0 0
Upto Week 54
Secondary outcome [17] 0 0
Change From Baseline in Weight
Timepoint [17] 0 0
Baseline (Week 0) and Weeks 4, 8, 12, 16, 24, 36, 48, 54
Secondary outcome [18] 0 0
Change From Baseline in Hemoglobin
Timepoint [18] 0 0
Baseline (Week 0) and Weeks 4, 16, 36, 48
Secondary outcome [19] 0 0
Change From Baseline in Hematocrit
Timepoint [19] 0 0
Baseline (Week 0) and Weeks 4, 16, 36, 48
Secondary outcome [20] 0 0
Any Time on Treatment Differences in Frequencies of Hematology Data Outside the Reference Range
Timepoint [20] 0 0
Up to Week 48
Secondary outcome [21] 0 0
Any Time on Treatment Differences in Frequencies of Clinical Chemistry Data Outside the Reference Range
Timepoint [21] 0 0
Upto Week 48
Secondary outcome [22] 0 0
Changes From Baseline in Electrocardiogram (ECG) Parameters- HR
Timepoint [22] 0 0
Baseline (Week 0) and Weeks 4, 8, 16, 24, 36, 48, 54
Secondary outcome [23] 0 0
Changes From Baseline in ECG Parameters- RR Interval, QT Interval, QTcB, QTcF, PR Interval and QRS Duration
Timepoint [23] 0 0
Baseline (Week 0) and Weeks 4, 8, 16, 24, 36, 48, 54
Secondary outcome [24] 0 0
Change From Baseline in HbA1c up to Week 54
Timepoint [24] 0 0
Baseline (Week 0) and Weeks 12, 24, 36, 48, 54
Secondary outcome [25] 0 0
Change From Baseline in Short Term Memory Assessment
Timepoint [25] 0 0
Baseline (Week 0) and upto Week 48

Eligibility
Key inclusion criteria
A subject will be eligible for inclusion in this study only if all of the following criteria apply:

* Male or female subject with a clinical diagnosis of probable Alzheimer's disease in accordance with NINCDS-ADRDA criteria (Appendix 2).

(Note: National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and Alzheimer's Disease and Related Disorders Association (ADRDA).)

* Subject has mild to moderate Alzheimer's disease as defined by a MMSE score 10 to 26 inclusive at Screening.
* Hachinski Ischemia Score = 4 at Screening (See Appendix 3).
* Age =50 and =90 years.
* At least 6 months of ongoing acetylcholinesterase inhibitor therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
* Current use of medication is in accordance with the criteria listed in Table 2 (Permitted Medications, Section 8.1).
* Female subjects must be post-menopausal (i.e. >1 year without menstrual period), surgically sterile, or agree to use adequate method of contraception (Appendix 4) for the duration of the study. Female subjects who are pre-menopausal or who have been post-menopausal for <1 year must undertake pregnancy testing (urine test) at Visit 1, which must be negative.
* Brain CT or MRI scan performed within the past 12 months or at Screening, showing no evidence of any other potential cause of dementia other than Alzheimer's disease.

(Note: Questionable CT or MRI scans should be discussed with the medical monitor, using central imaging guidelines.)

* Neurological exam without focal changes (excluding changes attributable to AD or peripheral trauma).
* Subject has the ability to comply with procedures for cognitive and other testing.
* Subject lives with (or has substantial periods of contact with) a regular caregiver who is willing to attend all visits, oversee the subject's compliance with protocol-specified procedures and study medication, and report on subject's status.

(Note: A non-cohabiting caregiver must spend sufficient time with the subject so that, in the opinion of the Investigator, the caregiver can reliably assess cognitive function, activities and behavior, and report on the subject's compliance and health. As caregiver time spent with a potential subject is anticipated to be highly variable across countries and cultures, GSK will consider a variety of different measures by which this stipulation may be met, and GSK should be consulted if adequacy of a caregiver situation is in doubt. However, as guidance, the ability for a caregiver to meet his/her expected responsibilities for this study would normally be possible when the caregiver spends no less than 10 hours per week with the subject, divided over multiple days.)

* Subject has provided full written informed consent prior to the performance of any protocol-specified procedure; or if unable to provide informed consent due to cognitive status, full written informed consent on behalf of the subject has been provided by a legally acceptable representative.

(Note: Consent by legally acceptable representative is allowed where this is in accordance with local laws, regulations and ethics committee policy.)

* Caregiver has provided full written informed consent on his/her own behalf prior to the performance of any protocol-specified procedure.
* Subjects considered for enrolment must have a QTc (either QTc B (Bazett's correction) or QTc F (Fridericia's correction)) <450msec at Visit 1, with the exception of subjects with bundle branch block (for whom either QTc B or QTc F must be <480msec).

(Note: For the purposes of these criteria, QTc B is defined as (QT interval [msec]) / (square root of RR interval [seconds]); and QTc F is defined as (QT interval [msec]) / (cube root of RR interval [seconds]).)
Minimum age
50 Years
Maximum age
90 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
A subject will not be eligible for inclusion in this study if any of the following criteria apply:

* Diagnosis of possible, probable, or definite vascular dementia in accordance with NINDS-AIREN criteria (Appendix 5).

(Note: National Institute of Neurological Disorders and Stroke (NINDS) and Association Internationale pour la Recherche et l'Enseignement en Neurosciences (AIREN).)

* History or evidence of any other CNS disorder that could be interpreted as a cause of dementia: e.g. cerebrovascular disease (stroke, hemorrhage), structural abnormality, epilepsy, infectious or inflammatory/demyelinating CNS conditions, Parkinson's disease.
* Evidence of the following disorders: current vitamin B12 deficiency, positive syphilis serology, or active thyroid dysfunction (particularly that suggestive of hypothyroidism), including abnormally high or low serum levels of thyroid stimulating hormone (TSH), that are clinically significant in the opinion of the investigator.

(Note: Testing is required for each parameter only when no result is available from previous 12 months.)

* History of Type 1 diabetes mellitus or secondary diabetes mellitus.
* Type 2 diabetes mellitus where the subject is being treated with insulin, a PPAR? agonist, or an insulin secretagogue (e.g. a sulfonylurea or glitinide).
* Any patient with an HbA1c =8.5%. (See Section 6.3.8.4 for Safety Measures for Enrolled Subjects with Type 2 Diabetes Mellitus.)
* History or clinical/investigational evidence of congestive heart failure defined by the New York Heart Association criteria (Class I to IV cardiac status; Appendix 6).
* History of cardiovascular event within the last 6 months (i.e. intervention, percutaneous coronary intervention, vascular surgery, acute coronary syndrome [non Q-wave myocardial infarction, Q-wave myocardial infarction, unstable angina] or significant arrhythmia; or major intervention (e.g. cardiac surgery or angiography plus stenting) scheduled).
* History of significant psychiatric illness such as schizophrenia or bipolar affective disorder that in the opinion of the Investigator would interfere with participation in the study, major depressive disorder (according to DSM-IV) in the past year, or current active depression requiring initiation of treatment.

(Note: If not currently treated, but active depression is suspected, the Cornell Scale for Depression in Dementia (CSDD, Appendix 7) can be used by the Investigator as a guide for deciding whether a prospective subject requires treatment. If the subject has a CSDD score >7, the Investigator should decide if the subject has depression in need of prescribed medication, and a CSDD >12 is considered a strong indicator that treatment is needed. Subjects will be allowed to re-screen after their depression has been adequately managed for >3 months.)

* History or presence of gastro-intestinal, hepatic, or renal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, or any other clinically relevant abnormality, medical or psychiatric condition, which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study.
* Clinically significant peripheral edema at the time of screening.
* Current or recent drug or alcohol abuse or dependence (defined by DSM-IV criteria for substance-related disorders), or recent or remote history of the same if that could be a contributing factor to the dementia.
* Systolic blood pressure >165 or <90 mmHg or diastolic blood pressure >95 or <60 mmHg at the time of screening.
* Clinically significant anemia (i.e. hemoglobin <11 g/dL for males or <10 g/dL for females) or presence of hemoglobinopathies which would prevent accurate assessment of HbA1c.
* Abnormal kidney function tests (>1.5 times the upper limit of normal (ULN)).
* ALT, AST, or alkaline phosphatase values >2.5 times the ULN, total bilirubin values >1.5 times the ULN, or history of severe hepatobiliary disease (e.g. hepatitis B or C, or cirrhosis, Child-Pugh Class B/C).

(Note: For subjects with a diagnosis of Gilberts Syndrome and an isolated increase in total bilirubin >1.5 ULN, fractionation should be performed. If all of the following conditions are met, the patient may enter or remain in the study, even if total bilirubin >1.5 ULN:

* an elevated unconjugated (indirect) bilirubin;
* the percentage of direct bilirubin <35%;
* ALT, AST, and alkaline phosphatase <2.5 ULN if subject is in screening (<2.0 ULN for Canadian subjects only), or =3 ULN if subject is already randomized into the study)
* History of a bone marrow transplant.
* Subject is unable (with assistance, if appropriate) to take study medication as prescribed throughout the study or is at risk of non-compliance with study medication or procedures.
* Subject is an immediate family member or employee of the participating Investigator, of any of the participating site staff, or of GSK.
* In France, a subject is neither affiliated with nor a beneficiary of a social security category.
* The French subject has participated in any study using an investigational drug during the previous 30 days or 5 half-lives (whichever is longer).
* Cognitive tasks prescribed for cognitive rehabilitation and performed under medical supervision are prohibited for 6 months prior to Screening, as well as for the duration of the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/07/2006
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
20/03/2009
Sample size
Target
Accrual to date
Final
1468
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
GSK Investigational Site - Hornsby
Recruitment hospital [2] 0 0
GSK Investigational Site - Randwick
Recruitment hospital [3] 0 0
GSK Investigational Site - Auchenflower
Recruitment hospital [4] 0 0
GSK Investigational Site - Chermside
Recruitment hospital [5] 0 0
GSK Investigational Site - Kippa Ring
Recruitment hospital [6] 0 0
GSK Investigational Site - Adelaide
Recruitment hospital [7] 0 0
GSK Investigational Site - Woodville
Recruitment hospital [8] 0 0
GSK Investigational Site - Cheltenham
Recruitment hospital [9] 0 0
GSK Investigational Site - Heidelberg West
Recruitment hospital [10] 0 0
GSK Investigational Site - Kew
Recruitment hospital [11] 0 0
GSK Investigational Site - Nedlands
Recruitment postcode(s) [1] 0 0
2077 - Hornsby
Recruitment postcode(s) [2] 0 0
2031 - Randwick
Recruitment postcode(s) [3] 0 0
4066 - Auchenflower
Recruitment postcode(s) [4] 0 0
4032 - Chermside
Recruitment postcode(s) [5] 0 0
4021 - Kippa Ring
Recruitment postcode(s) [6] 0 0
5000 - Adelaide
Recruitment postcode(s) [7] 0 0
5011 - Woodville
Recruitment postcode(s) [8] 0 0
3192 - Cheltenham
Recruitment postcode(s) [9] 0 0
3084 - Heidelberg West
Recruitment postcode(s) [10] 0 0
3101 - Kew
Recruitment postcode(s) [11] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
New Jersey
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Oklahoma
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
Rhode Island
Country [16] 0 0
United States of America
State/province [16] 0 0
South Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Utah
Country [19] 0 0
United States of America
State/province [19] 0 0
Virginia
Country [20] 0 0
United States of America
State/province [20] 0 0
Washington
Country [21] 0 0
United States of America
State/province [21] 0 0
Wisconsin
Country [22] 0 0
Belgium
State/province [22] 0 0
Bruxelles
Country [23] 0 0
Belgium
State/province [23] 0 0
Kortrijk
Country [24] 0 0
Belgium
State/province [24] 0 0
Leuven
Country [25] 0 0
Belgium
State/province [25] 0 0
Woluwe-Saint-Lambert
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Sofia
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Varna
Country [28] 0 0
Canada
State/province [28] 0 0
British Columbia
Country [29] 0 0
Canada
State/province [29] 0 0
New Brunswick
Country [30] 0 0
Canada
State/province [30] 0 0
Nova Scotia
Country [31] 0 0
Canada
State/province [31] 0 0
Ontario
Country [32] 0 0
Canada
State/province [32] 0 0
Quebec
Country [33] 0 0
Canada
State/province [33] 0 0
Québec
Country [34] 0 0
Czechia
State/province [34] 0 0
Olomouc
Country [35] 0 0
Czechia
State/province [35] 0 0
Praha 10
Country [36] 0 0
Czechia
State/province [36] 0 0
Praha 8
Country [37] 0 0
Czechia
State/province [37] 0 0
Trutnov
Country [38] 0 0
Finland
State/province [38] 0 0
Helsinki
Country [39] 0 0
Finland
State/province [39] 0 0
Joensuu
Country [40] 0 0
Finland
State/province [40] 0 0
Kuopio
Country [41] 0 0
France
State/province [41] 0 0
Bordeaux
Country [42] 0 0
France
State/province [42] 0 0
La Chapelle sur Erdre
Country [43] 0 0
France
State/province [43] 0 0
La Seyne sur Mer
Country [44] 0 0
France
State/province [44] 0 0
Lille
Country [45] 0 0
France
State/province [45] 0 0
Limoges
Country [46] 0 0
France
State/province [46] 0 0
Metz
Country [47] 0 0
France
State/province [47] 0 0
Nantes
Country [48] 0 0
France
State/province [48] 0 0
Paris
Country [49] 0 0
France
State/province [49] 0 0
Sautron
Country [50] 0 0
France
State/province [50] 0 0
Toulon
Country [51] 0 0
France
State/province [51] 0 0
Toulouse
Country [52] 0 0
France
State/province [52] 0 0
Valence
Country [53] 0 0
Germany
State/province [53] 0 0
Baden-Wuerttemberg
Country [54] 0 0
Germany
State/province [54] 0 0
Bayern
Country [55] 0 0
Germany
State/province [55] 0 0
Brandenburg
Country [56] 0 0
Germany
State/province [56] 0 0
Hessen
Country [57] 0 0
Germany
State/province [57] 0 0
Sachsen
Country [58] 0 0
Germany
State/province [58] 0 0
Thueringen
Country [59] 0 0
Germany
State/province [59] 0 0
Berlin
Country [60] 0 0
Hong Kong
State/province [60] 0 0
Hong Kong
Country [61] 0 0
Hong Kong
State/province [61] 0 0
Shatin
Country [62] 0 0
Korea, Republic of
State/province [62] 0 0
Seongnam-si,
Country [63] 0 0
Korea, Republic of
State/province [63] 0 0
Seoul
Country [64] 0 0
Malaysia
State/province [64] 0 0
Bandar Tun Razak, Cheras
Country [65] 0 0
Malaysia
State/province [65] 0 0
Ipoh
Country [66] 0 0
Malaysia
State/province [66] 0 0
Kelantan
Country [67] 0 0
Netherlands
State/province [67] 0 0
Alkmaar
Country [68] 0 0
Netherlands
State/province [68] 0 0
Blaricum
Country [69] 0 0
Netherlands
State/province [69] 0 0
Den Bosch
Country [70] 0 0
Netherlands
State/province [70] 0 0
Den Haag
Country [71] 0 0
Netherlands
State/province [71] 0 0
Hengelo
Country [72] 0 0
Netherlands
State/province [72] 0 0
Hilversum
Country [73] 0 0
Philippines
State/province [73] 0 0
Manila
Country [74] 0 0
Philippines
State/province [74] 0 0
Pasig City
Country [75] 0 0
Poland
State/province [75] 0 0
Bydgoszcz
Country [76] 0 0
Poland
State/province [76] 0 0
Krakow
Country [77] 0 0
Poland
State/province [77] 0 0
Torun
Country [78] 0 0
Poland
State/province [78] 0 0
Warsaw
Country [79] 0 0
Singapore
State/province [79] 0 0
Singapore
Country [80] 0 0
Slovakia
State/province [80] 0 0
Bratislava
Country [81] 0 0
Slovakia
State/province [81] 0 0
Kosice
Country [82] 0 0
Slovenia
State/province [82] 0 0
Ljubljana
Country [83] 0 0
Slovenia
State/province [83] 0 0
Šempeter
Country [84] 0 0
South Africa
State/province [84] 0 0
Loeventstein
Country [85] 0 0
South Africa
State/province [85] 0 0
Oakdale
Country [86] 0 0
South Africa
State/province [86] 0 0
Richards Bay
Country [87] 0 0
South Africa
State/province [87] 0 0
Rosebank
Country [88] 0 0
South Africa
State/province [88] 0 0
Somerset West
Country [89] 0 0
South Africa
State/province [89] 0 0
Waverley, Bloemfontein
Country [90] 0 0
South Africa
State/province [90] 0 0
Willows, X14, Pretoria
Country [91] 0 0
Spain
State/province [91] 0 0
Baracaldo/Vizcaya
Country [92] 0 0
Spain
State/province [92] 0 0
Barcelona
Country [93] 0 0
Spain
State/province [93] 0 0
Palma de Mallorca
Country [94] 0 0
Spain
State/province [94] 0 0
Tarrasa, Barcelona
Country [95] 0 0
Sweden
State/province [95] 0 0
Falköping
Country [96] 0 0
Sweden
State/province [96] 0 0
Jönköping
Country [97] 0 0
Sweden
State/province [97] 0 0
Kalix
Country [98] 0 0
Sweden
State/province [98] 0 0
Mölndal
Country [99] 0 0
Sweden
State/province [99] 0 0
Sundsvall
Country [100] 0 0
Sweden
State/province [100] 0 0
Umeå
Country [101] 0 0
United Kingdom
State/province [101] 0 0
Lancashire
Country [102] 0 0
United Kingdom
State/province [102] 0 0
Bradford
Country [103] 0 0
United Kingdom
State/province [103] 0 0
Liverpool
Country [104] 0 0
United Kingdom
State/province [104] 0 0
Stirling
Country [105] 0 0
United Kingdom
State/province [105] 0 0
West End, Southampton
Country [106] 0 0
United Kingdom
State/province [106] 0 0
West of Scotland Science Park, Glasgow

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG.

This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer's disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one's genetic makeup affects the response to the study drug. Clinical data suggesting that RSG may benefit AD patients was first seen in a small study performed at the University of Washington and then from a larger GSK study conducted in Europe and New Zealand. In the first study, subjects receiving RSG once daily for 6 months scored significantly better on 3 tests of memory and thought than those who did not receive RSG. In the GSK study, those that appeared to benefit most from treatment with RSG XR had a specific genetic pattern. They did not have the gene that caused them to produce the protein apolipoprotein E e4 (APOE e4). Subjects who have the APOE e4 gene may have two copies, one from each parent, or they may have only one APOE e4 gene meaning that they inherited either the APOE e2 or APOE e3 version of the gene, instead of APOE e4, from one of their parents. Subjects with one copy of the APOE e4 gene remained at their same level of thinking ability while those with two copies of the APOE e4 gene, continued to worsen during the 6-month treatment. The current study will more directly test the effectiveness or RSG XR on people who either have or lack the APOE e4 gene.
Trial website
https://clinicaltrials.gov/study/NCT00348140
Trial related presentations / publications
Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Curr Alzheimer Res. 2011 Aug;8(5):592-606. doi: 10.2174/156720511796391935.
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00348140